A new systematic review suggests that bacteria living inside pancreatic tumors may play a key role in how the cancer progresses and responds to treatment. Researchers analyzed existing studies on the intratumoral microbiome, the community of microbes found within tumor tissue. They found that these bacteria are mainly from two groups, Proteobacteria and Firmicutes. The composition of these microbes was significantly linked to patient survival.
The review also describes several ways the bacteria may drive tumor growth and chemotherapy resistance. For example, they can remodel the immune environment around the tumor, damage DNA, and activate cancer-promoting signals. They may also help tumors resist chemotherapy by altering the surrounding tissue and even breaking down the drugs themselves.
It is important to note that this is a review of existing research, not a new clinical trial. The findings show associations and describe possible mechanisms, but they do not prove that changing the microbiome will improve outcomes. No specific treatments targeting these bacteria have been tested in patients yet.
For now, this research highlights a promising area for future study. Patients with pancreatic cancer should continue to follow their doctor's advice on standard treatments. This work may eventually lead to new therapies, but more research is needed.
